“Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab”, J of Skin, vol. 1, no. 3.1, p. s5, Oct. 2017, doi: 10.25251/skin.1.supp.4.